Who
Michael Seth Altman
Other role
Company insider
Files Form 4 as: Chief Business Officer, Freenome; Chief Financial Officer, ARYA Sciences Acquisition Corp IV; Chief Financial Officer, Nautilus Biotechnology; Director, Lyra Therapeutics; Chief Financial Officer, ARYA Sciences Acquisition Corp V; Chief Financial Officer, ARYA Sciences Acquisition Corp II.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 1
- First trade
- 30 Apr 2020
- Last trade
- 20 Jul 2026
- Last filed
- 22 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Jul 2026filed 22 Jul 2026 | FRNM FreenomeDiagnostics & Labs | SEC FORM 4 Code C | —2,066,250 | filing |
| 20 Jul 2026filed 22 Jul 2026 | FRNM Freenomeoption or derivative · Diagnostics & Labs | SEC FORM 4 Code C | —2,066,250 | filing |
| 20 Jul 2026filed 22 Jul 2026 | FRNM Freenomeoption or derivative · Diagnostics & Labs | SEC FORM 4 Code C | —2,066,250 | filing |
| 20 Jul 2026filed 22 Jul 2026 | FRNM FreenomeDiagnostics & Labs | SEC FORM 4 Code C | —2,066,250 | filing |
| 31 Jul 2024filed 31 Jul 2024 | ARYA Sciences Acquisition Corp IVoption or derivative | SEC FORM 4 Code D | —1,000,000 | filing |
| 31 Jul 2024filed 31 Jul 2024 | ARYA Sciences Acquisition Corp IVoption or derivative | SEC FORM 4 Code D | —2,647,500 | filing |
| 31 Jul 2024filed 31 Jul 2024 | ARYA Sciences Acquisition Corp IV | SEC FORM 4 Code D | —499,000 | filing |
| 14 Jun 2024filed 17 Jun 2024 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 13 Jun 2024filed 13 Jun 2024 | FRNM FreenomeDiagnostics & Labs | SEC FORM 4 Code A | $2.9M286,250 at $10.00 | filing |
| 30 Jun 2023filed 5 Jul 2023 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —7,250 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —86,467 at $0.00 | filing |
| 15 Jul 2021filed 15 Jul 2021 | ARYA Sciences Acquisition Corp V | SEC FORM 4 Code A | $5.0M499,000 at $10.00 | filing |
| 9 Jun 2021filed 11 Jun 2021 | NAUT Nautilus BiotechnologyLife-science tools | SEC FORM 4 Code C | —3,647,500 | filing |
| 9 Jun 2021filed 11 Jun 2021 | NAUT Nautilus BiotechnologyLife-science tools | SEC FORM 4 Code C | —499,000 | filing |
| 9 Jun 2021filed 11 Jun 2021 | NAUT Nautilus BiotechnologyLife-science tools | SEC FORM 4 Code C | —499,000 | filing |
| 9 Jun 2021filed 11 Jun 2021 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code C | —3,647,500 | filing |
| 9 Jun 2021filed 11 Jun 2021 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —44,435 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.